Pharmacyclics Inc. (NASDAQ: PCYC) has seen its stock surge in the past week as rumors swirl about a potential acquisition. News finally broke late Wednesday that there was an official buyout in the works by AbbVie Inc. (NYSE: ABBV) for $21 billion.
Note that this is AbbVie’s first major deal attempt since last fall, when it attempted a takeover of Shire PLC (NASDAQ: SHPG) for $55 billion.
Some analysts saw this coming and issued calls leading up to the announcement. Others are just reacting to it. 24/7 Wall St. has included information from the Credit Suisse report and tagged a few other calls that have been made.
Credit Suisse detailed that it likes AbbVie’s diversification strategy, which it indicated in its “surprising” $21 billion acquisition of Pharmacyclics and its blood-cancer drug Imbruvica. However, the brokerage firm is bearish on the price.
It is not hard to be bearish on the price, considering Pharmacyclics shares have increased 88.5% year-to-date. Looking back even further, this was just a $10 stock in 2011.
The investment bank calls the deal size “manageable” and possibly “highly accretive” by 2017. But the price, given Pharmacyclics’ 50-50 profit split with Johnson & Johnson (NYSE: JNJ) on Imbruvica, “seems to imply some degree of success for Imbruvica in other indications where there is limited human clinical data.”
ALSO READ: The 5 Most Loved Biotech Stocks of Portfolio Managers
In the week leading up to the announcement, these analysts made calls when the buyout was only suspected:
- WallachBeth Capital downgraded shares to Hold from Buy on February 26.
- Goldman Sachs downgraded Pharmacyclics to Neutral from Buy on February 27.
- Wedbush downgraded shares to Neutral from Outperform with a price target of $234, up from $225, on March 3.
A couple of analysts weighed in after the announcement:
- BTIG Research downgraded Pharmacyclics to Neutral from Buy.
- RBC Capital maintained a Sector Perform rating and raised its price target to $261 from $145.
Shares of Pharmacyclics were up about 10.6% at $254.84 Thursday morning. The stock has a consensus analyst price target of $196.95 and a 52-week trading range of $82.51 to $255.52.
Credit card companies are handing out rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
